背景:免疫接种,作为传染病的预防策略,巩固了其作为公共卫生领域基本支柱的地位。因此,本研究旨在确定接受猴痘(Mpox)疫苗的意向发生率.
方法:使用五个数据库(PubMed,Scopus,WebofScience,Embase,和ScienceDirect)的搜索策略到2023年7月24日。在R软件版本4.2.3中进行数据分析。纳入的横断面研究的质量使用“JBI-MAStARI”进行评估。此外,按人口和大陆进行了亚组分析。
结果:纳入了29篇横断面文章,共52658名参与者。计划接种水痘的总患病率为61%(95%CI:53-69%;52,658名参与者;29项研究;I2=100%)。在亚组分析中,根据各大洲,在亚洲国家,接种水痘的意向为64%(95%CI:53-74%;13,883名参与者;17项研究;I2=99%),43%(95%CI:39-47%;1538名参与者;3项研究;I2=53%)在非洲国家,62%(95%CI:45-78%;35,811名参与者;6项研究;I2=99%)在欧洲国家,和63%(95%CI:32-89%;1426名参与者;3项研究;I2=99%)在美国国家。在对接种水痘疫苗的意图的亚组分析中,根据研究对象,在一般人群中为54%(95%CI:45-62%;10,296名参与者;11项研究;I2=99%),57%(95%CI:33-79%;3333名参与者;10项研究;I2=99%)在医护人员中,和76%(95%CI:70-82%;39,029名参与者;8项研究;I2=98%)在女同性恋中,同性恋,双性恋,变性人,双性恋(LGBTI)社区。此外,作为次要结果,发现拒绝水痘疫苗接种的患病率为22%(95%CI:16-30%;45,577名参与者;21项研究;I2=99%).
结论:该研究强调了认识到水痘疫苗意愿和拒绝的区域和亚组差异的重要性。它强调了采用战略实现广泛疫苗接种覆盖率和维护全球公共卫生的重要性。
■JoannaBriggsInstituteMeta分析统计评估和审查工具(JBI-MAStARI),前瞻性国际系统审查登记处(PROSPERO),系统评价和荟萃分析(PRISMA)的首选报告项目。
Immunization, as a preventive strategy against infectious diseases, has consolidated its position as a fundamental pillar in the field of public health. Therefore, the present study aimed to determine the prevalence of the intention to receive the monkeypox (Mpox) vaccine.
A systematic
review and meta-analysis of the available evidence was performed using five databases (PubMed, Scopus, Web of Science, Embase, and ScienceDirect) with a search strategy until July 24, 2023. Data analysis was performed in R software version 4.2.3. The quality of the included cross-sectional studies was assessed using the \"JBI-MAStARI\". In addition, a subgroup analysis by population and continent was developed.
Twenty-nine cross-sectional articles with a total sample of 52 658 participants were included. The pooled prevalence of intention to vaccinate against Mpox was 61% (95% CI: 53-69%; 52,658 participants; 29 studies; I2 = 100%). In the subgroup analysis, the intention to be vaccinated against Mpox according to continents was 64% (95% CI: 53-74%; 13,883 participants; 17 studies; I2 = 99%) in Asian countries, 43% (95% CI: 39-47%; 1538 participants; 3 studies; I2 = 53%) in African countries, 62% (95% CI: 45-78%; 35,811 participants; 6 studies; I2 = 99%) in European countries, and 63% (95% CI: 32-89%; 1426 participants; 3 studies; I2 = 99%) in American countries. In the subgroup analysis on the intention to be vaccinated against Mpox, according to study subjects, it was 54% (95% CI: 45-62%; 10,296 participants; 11 studies; I2 = 99%) in the general population, 57% (95% CI: 33-79%; 3333 participants; 10 studies; I2 = 99%) in health care workers, and 76% (95% CI: 70-82%; 39,029 participants; 8 studies; I2 = 98%) in the lesbian, gay, bisexual, transgender, and intersex (LGBTI) community. In addition, as a secondary outcome, a prevalence of refusal of Mpox vaccination was found to be 22% (95% CI: 16-30%; 45,577 participants; 21 studies; I2 = 99%).
The study highlights the importance of recognizing regional and subgroup disparities in Mpox vaccine willingness and refusal. It emphasizes the importance of employing strategies to achieve widespread vaccination coverage and safeguard public health worldwide.
Joanna Briggs Institute Meta-Analysis of Statistics Assessment and
Review Instrument (JBI-MAStARI), Prospective International Registry of Systematic Reviews (PROSPERO), and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).